Drug-induced immunosuppression-while profoundly compromising the cytotoxic response of the adaptive immune system, as in organ transplant recipient (OTR) rejection-apparently impairs the inflammatory environment of SCC to a lesser degree. While tumor defense such as a cytotoxic response of the adaptive immune system seems impaired in SCC in OTRs, a persistent inflammatory feed-forward loop via RAGE may contribute to uncontrolled SCC formation in OTRs.
Intralesional Immunotherapy With Mycobacterium w Vaccine in Patients With Multiple Cutaneous Warts: Uncontrolled Open Study
Methods. Prior approval was obtained for the study from the institutional review board, and each patient provided written informed consent prior to study entry. Forty patients with multiple cutaneous warts (Ն3) were then included in an open-label, interventional study conducted at the Department of Dermatology, Venereology, and Leprology of Sawai ManSingh (S.M.S.) Medical College, Jaipur, India, from December 2010 to August 2011 (8 months). Pregnant women, lactating mothers, children younger than 12 years, patients with a history of hypersensitivity or allergy to vaccines, and those with ulcerated or inflamed warts were excluded from the study. were applied to human primary keratinocytes for 12 hours, and thereafter, messenger RNA (mRNA) extraction and real-time polymerase chain reaction analysis was performed. After 12 hours of CsA incubation S100A8 (A) and S100A9 (B) mRNA levels were increased. The expression of RAGE mRNA was slightly but significantly decreased (C), while the expression of NFB remained unchanged (D). The graphs show mean (SD) relative expression. *P Ͻ .05; †P Ͻ .01.
The demographic data, complete medical history, and findings of clinical examination, including a lesion count and photographic documentation, were recorded for all patients at baseline (J.K.M.). The Mycobacterium w (Mw) vaccine (IMMUVAC; Cadila Pharmaceuticals, Licensed by National Institute of Immunology, New Delhi, India) was administered intradermally at a dose of 0.1 mL, using an insulin syringe, in each deltoid at baseline. After 2 weeks, the injected sites were examined for immunologic reaction (induration and or ulceration at the site of intradermal injection). In sensitized patients, the Mw vaccine was injected intralesionally into 3 to 5 lesions (lesions chosen at random) and repeated every week until either complete clearance of warts or a maximum of 10 injections (12 weeks), whichever was earlier. Lesion count and response data from the injected lesions as well as untreated lesions were recorded at each follow-up visit along with adverse events (if any). Table. Thirty-seven of 40 patients completed the study; 3 patients were lost to follow-up, one each at weeks 2, 3, and 4. Complete clearance of warts was seen in 33 (83%) patients (Figure 1 and Figure 2) ; 1 patient had 50% clearance, while 3 patients had only 25% to 30% reduction in number of lesions. The mean (SD) time to complete clearance was 9.7 (2.6) weeks. Twenty-three of 33 patients showed resolution of distant untreated warts (70%); in the remaining 10 patients, all lesions received intralesional Mw vaccine. Recurrence was seen in 3 patients during the posttreatment follow-up period of 4.48 (1.32) months.
Results. The demographic and clinical data of patients are listed in the
Tender erythematous papules and/or pustules developed at the site of sensitization in all patients, and it healed leaving a small BCG vaccine-like scar. Erythema in the treated warts was the most common adverse effect, seen in 25 patients (70%), followed by swelling in 6 patients (16%). Superficial ulceration at the site of treated warts was seen in 1 patient. Two patients reported low-grade fever not associated with any systemic symptoms only on the day when the Mw vaccine was given intralesionally in the warts from the fourth week onward. Two patients who received intralesional Mw vaccine injection on facial lesions developed tenderness and swelling of submandibular lymph nodes, and their treatment was discontinued for 2 weeks. Patients recovered completely under treatment with oral amoxicillin/clavulanic acid, 625 mg combination therapy 3 times a day for 5 days.
Comment. Treatment of multiple and extensive cutaneous warts is a challenge. Intralesional immunotherapy with Candida antigen, BCG vaccine, MMR vaccine (measles, mumps, rubella) and Trichophyton has been reported to be effective in the treatment of cutaneous and/or genital warts. 1 We used Mw vaccine that contains killed nonpathogenic, saprophytic, cultivable, atypical mycobacterium belonging to Runyon Group IV, which has now been renamed Mycobacterium indicus pranii (MIP).
2 Mycobacterium w vaccine is primarily used for immunotherapy of multibacillary leprosy, but its immunomodulatory effects have also been demonstrated in other mycobacterial infections such as pulmonary tuberculosis, human immunodeficiency infection and malignant neoplasms of the head, neck, bladder, and lung. [3] [4] [5] [6] Our research team has previously reported an 88.9% cure rate with Mw vaccine in genital warts. 7 The exact mechanism of the wart clearance with Mw vaccine is yet to be studied. The strong proinflammatory signals against Mw attract antigen-presenting cells with production of helper T-cell type 1 cytokines and activation of cytotoxic and natural killer T cells that probably also recognize and process low-profile human papillomavirus particles in the infected tissue. 7 The strong adaptive immune response clears not only treated lesions but also distant lesions. Mw vaccine appears to be an effective immunotherapy for extensive and multiple cutaneous warts, and it should be further evaluated in randomized controlled trials.
Recurrence After Treatment of Cutaneous Basal Cell and Squamous Cell Carcinomas in Patients Infected With Human Immunodeficiency Virus
C utaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), collectively called nonmelanoma skin cancer (NMSC), are the most common primary malignant neoplasms, yet recurrence after treatment is unusual. 1 With modern antiretroviral therapy, NMSC is also the most frequent cancer in persons infected with human immunodeficiency virus (HIV), 2 but recurrence rates in this population are largely unknown. 3 We followed a large prospective cohort of patients with NMSC to determine tumor recurrence rates and found unexpectedly high recurrence among the HIVinfected patients.
Methods. This study was approved by the committee on human research, University of California, San Francisco, and details of this study have been described elsewhere. 1 Briefly, eligible patients were those with primary NMSC diagnosed in 1999 or 2000 at a university-based practice and its affiliated Veterans Affairs Medical Center. Data were collected via medical records, patient survey, and blinded physical examination, and patients were followed up for a median (interquartile range [IQR]) of 7.3 (3.1-8.7) years after treatment. Given the prevalence of human papilloma virus-associated genital SCCs among HIV-infected patients, tumors located in the genital area were excluded from all analyses.
We compared groups by the 2 test for categorical characteristics and Wilcoxon rank sum test for continuous characteristics. Cumulative incidence of tumor recurrence over time was displayed using Kaplan-Meier plots. We also constructed a series of Cox proportional hazard models to calculate unadjusted and adjusted 5-year recurrence rates and hazard ratios (HRs). Because of the limited number of recurrences, we forced HIV status and treatment type (categorized as conservative [destruction, topical, or none] or aggressive [excisional or Mohs surgery]) into the adjusted models then applied a forward stepwise selection based on AIC (Akaike Information Criterion) within the entire sample and each histological subtype (BCC and SCC). Potentially selected variables were those significant in bivariate analyses, including age, history of prior NMSC, multiple NMSCs at enrollment, tumor location in the H-zone of the face-a high-risk area for recurrence-histologic type, histologic invasiveness, and number of annual visits to a dermatologist throughout the follow-up period. Unadjusted analyses were repeated in an SCC subset matched at a 1:5 ratio, HIV-infected to HIV-uninfected, on age, sex, and tumor body location. Statistical analyses were performed using R statistical software, version 2.13. 
Results

